Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00411801
Status:
TERMINATED
Last Update Posted:
2017-06-21
First Post:
2006-12-13
Brief Title:
Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura TTP
Sponsor:
Octapharma
Organization:
Octapharma
Study Overview
Official Title:
A Blinded Non-inferiority Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura TTP
Status:
TERMINATED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prior to the use of plasma products thrombotic thrombocytopenic purpura TTP was usually a fatal condition During plasma exchange therapy patients need transfusion plasma that is blood group specific Transfusing a patient with an incorrect blood group may have fatal consequences Uniplas is a universally applicable human plasma which can be administered irrespective of the patients blood group This study will test the safety and efficacy of Uniplas in comparison to cryosupernatant plasma in treatment of patients with TTP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None